0
BioNTech SE (NASDAQ:BNTX) on Monday reported fourth-quarter per-share earnings of 1.08 euros ($1.17), down from 1.88 euros reported a year ago compared to the consensus of 38 cents.
The COVID-19 vaccine maker reported sales of 1.19 billion euros, compared to 1.48 billion euros, beating consensus of 1.09 billion.
The revenue decrease was primarily driven by lower sales of the company’s COVID-19 vaccines due to reduced market demand.
In addition, write-downs by BioNTech’s collaboration partner Pfizer Inc (NYSE:PFE) significantly reduced the company’s gross profit share which negatively influenced its revenues.
